Treatment with the trifunctional antibody catumaxomabsignificantly prolongs puncture-free survival in patients with malignantascites, according to the results from a Phase II/III trial presented at the44th American Society of Clinical Oncology (ASCO) congress. The prolongedtime to next therapeutic puncture and reduced ascites signs and symptomsemphasize the clinical relevance of catumaxomab treatment.